Can adding immunotherapy to chemotherapy shrink pancreatic tumors before surgery?

NCT ID NCT05132504

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with standard FOLFIRINOX chemotherapy before surgery can help shrink tumors in people with resectable pancreatic cancer. The study enrolls adults with localized, potentially resectable pancreatic ductal adenocarcinoma. Participants receive six cycles of FOLFIRINOX, then pembrolizumab every six weeks, followed by surgery. The main goal is to see if this combination improves the overall response rate compared to historical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) combined with FOLFIRINOX chemotherapy
What this could lead to: If successful, this approach could improve tumor shrinkage and surgical outcomes for people with resectable pancreatic cancer, potentially extending survival.
What could go wrong: This is a small phase II trial, so results may not be conclusive. Adding immunotherapy to chemotherapy may increase side effects, and the benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Baylor College of Medicine
RECRUITING

Houston, Texas, 77030, United States
Baylor St. Luke's Medical Center (BSLMC).
RECRUITING

Houston, Texas, 77030, United States
Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.